Sublingual immunotherapy: from biological extracts to recombinant allergens

Sublingual vaccines based on biological extracts from various natural allergen sources are effective in the treatment of respiratory allergies. These vaccines comprise a complex mixture of proteins and glycoproteins that require dedicated standardization procedures to ensure batch‐to‐batch consisten...

Full description

Saved in:
Bibliographic Details
Published in:Allergy (Copenhagen) 2006-07, Vol.61 (s81), p.15-19
Main Author: Moingeon, P.
Format: Article
Language:English
Subjects:
Administration, Sublingual
allergen standardization
Allergens - administration & dosage
Allergens - genetics
Allergens - immunology
Desensitization, Immunologic
Humans
Langerhans Cells - immunology
Quality Control
recombinant allergens
Respiratory Hypersensitivity - immunology
Respiratory Hypersensitivity - therapy
sublingual immunotherapy
T-Lymphocytes, Regulatory - immunology
therapeutic vaccine
Vaccines, Synthetic - administration & dosage
Vaccines, Synthetic - immunology
Vaccines, Synthetic - standards
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sublingual vaccines based on biological extracts from various natural allergen sources are effective in the treatment of respiratory allergies. These vaccines comprise a complex mixture of proteins and glycoproteins that require dedicated standardization procedures to ensure batch‐to‐batch consistency. Because of the lack of correlation between the potency of an allergen extract and the quantity of major allergen content, standardization is achieved predominantly by determining the global IgE binding capacity of the extract in vitro. New proteomic technologies can be used to further characterize the most abundant proteins present in an extract. Second‐generation sublingual vaccines based on recombinant allergens are under development. The aim is to produce molecularly defined vaccines that exhibit superior efficacy, while allowing for simplified immunization schedules. In this approach, recombinant DNA technology is used to express highly purified allergens in their native (i.e. wild‐type) conformation. The recombinant allergens are then formulated with ad hoc adjuvants and/or mucoadhesive galenic excipients so that they specifically target oral Langerhans cells and induce allergen‐specific regulatory T cells.
ISSN:0105-4538
1398-9995
DOI:10.1111/j.1398-9995.2006.01157.x